mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity

Federica Finetti¹, Erika Terzuoli¹, Antonio Giachetti¹, Raffaella Santi², Donata Villari³, Hiromi Hanaka⁴, Olof Radmark⁴, Marina Ziche^{1,5} and Sandra Donnini^{1,5}

¹Department of Life Sciences, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy

²Department of Surgery and Translational Medicine, University of Florence, Largo Brambilla 3, 50134 Firenze, Italy

³Department of Clinical and Experimental Medicine, University of Florence, Viale Pieraccini 18, 50139 Firenze, Italy

⁴Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden

⁵Istituto Toscano Tumori (ITT), Firenze, Italy

Correspondence should be addressed to S Donnini or M Ziche
Emails
sandra.donnini@unisi.it or marina.ziche@unisi.it

Abstract

There is evidence that an inflammatory microenvironment is associated with the development and progression of prostate cancer (PCa), although the determinants of intrinsic inflammation in PCa cells are not completely understood. Here we investigated whether expression of intrinsic microsomal PGE synthase-1 (mPGES-1) enhanced aggressiveness of PCa cells and might be critical for epidermal growth factor receptor (EGFR)-mediated tumour progression. In PCa, overexpression of EGFR promotes metastatic invasion and correlates with a high Gleason score, while prostaglandin E₂ (PGE₂) has been reported to modulate oncogenic EGFR-driven oncogenicity. Immunohistochemical studies revealed that mPGES-1 in human prostate tissues is correlated with EGFR expression in advanced tumours. In DU145 and PC-3 cell lines expressing mPGES-1 (mPGES-1^{SC} cells), we demonstrate that silencing or 'knock down' of mPGES-1 (mPGES-1^{KD}) or pharmacological inhibition by MF63 strongly attenuates overall oncogenic drive. Indeed, mPGES-1^{SC} cells express stem-cell-like features (high CD44, β 1-integrin, Nanog and Oct4 and low CD24 and α 6-integrin) as well as mesenchymal transition markers (high vimentin, high fibronectin, low E-cadherin). They also show increased capacity to survive irrespective of anchorage condition, and overexpress EGFR compared to mPGES-1^{KD} cells. mPGES-1 expression correlates with increased *in vivo* tumour growth and metastasis. Although EGFR inhibition reduces mPGES-1^{SC} and mPGES-1^{KD} cell xenograft tumour growth, we show that mPGES-1/PGE₂ signalling sensitizes tumour cells to EGFR inhibitors. We propose mPGES-1 as a possible new marker of tumour aggressiveness in PCa.

Key Words

- mPGES-1
- prostate cancer
- stemness
- EGFR
- EMT

Endocrine-Related Cancer
(2015) 22, 665–678

Introduction

Prostate cancer (PCa) is currently treated with androgen deprivation and chemotherapeutic agents. Resistance to chemotherapy, a mounting issue in clinical oncology due to its association with tumour recurrence, has hastened

the search for new prognostic biomarkers and new therapeutic targets aimed at patient stratification in relation to treatment (Schrecengost & Knudsen 2013, Augello *et al.* 2014). Because ~40% of PCas express

epidermal growth factor receptor (EGFR), expression of which is correlated with tumour recurrence and high Gleason score, the receptor is assumed to be a potential molecular target for advanced PCa. However, clinical trials in PCa patients have shown limited efficacy of EGFR-targeted drugs (Canil *et al.* 2005, Hammarsten *et al.* 2007, Schlomm *et al.* 2007, Gravis *et al.* 2008, Nabhan *et al.* 2009). Multiple mechanisms, such as unrestrained expression of EGFR, emergence of oncogenic mutants (KRAS, BRAF and PIK3CA) and inactivation of the PTEN tumour suppressor gene, underlie resistance to these drugs. Acquired EGFR antagonist resistance is often associated with the activation of bypass signalling pathways typically embedded in tumour cells or the surrounding tissue (Arteaga 2002, Wieduwilt & Moasser 2008, Cathomas *et al.* 2012, Seshacharyulu *et al.* 2012).

Inflammatory molecules have been shown to enhance EGFR oncogenic action in epithelial tumours, fostering their propensity to metastasize. Many studies on the link between inflammation and cancer have dealt with stimuli originating from the cancer microenvironment (extrinsic), providing strong support for this mechanism (Mantovani *et al.* 2008, Hanahan & Weinberg 2011, Coussens *et al.* 2013).

Microsomal PGE synthase-1 (mPGES-1), known to be induced in inflammatory as well as tumour cells by pro-inflammatory cytokines, such as interleukin-1 beta (IL-1 β) and tumour necrosis factor alpha (TNF α), contributes in a critical way to tumour progression (Jakobsson *et al.* 1999, van Rees *et al.* 2003, Takeda *et al.* 2004, Kamei *et al.* 2009, Xu *et al.* 2012, Sha *et al.* 2013, Takahashi *et al.* 2014). We recently found that EGFR activation up-regulates mPGES-1, which in turn promotes phosphorylation of EGFR through prostaglandin E₂ (PGE₂) (Donnini *et al.* 2012).

Here we investigated whether expression of intrinsic mPGES-1 in advanced PCa cells enhanced their aggressiveness and might be critical for EGFR-mediated tumour progression. To begin to understand the mechanism underlying enhanced prostate oncogenic drive exerted by mPGES-1, we first examined human PCa specimens obtained after prostatectomy in a group of patients showing various stages of malignancy. The close association between mPGES-1 and EGFR expression observed in these tumours led us to detailed study of this connection in experiments on hormone-independent PCa cells DU145 and PC-3 *in vitro* and *in vivo*. We demonstrate that these cells have a mesenchymal phenotype and stem-like features, which are likely to confer aggressive traits. Evidence that intrinsic mPGES-1 underpins these traits is seen in cell cultures in which ablation of the mPGES-1

gene (DU145 mPGES-1^{KD}) or inhibition of mPGES-1 activity prevents development of a vigorous tumorigenic phenotype. The enhanced oncogenic drive observed *in vitro* translated to nude mice *in vivo* inoculated with DU145 or PC-3 cells, as we found significantly higher tumour growth and lung metastasis formation in mice inoculated with PCa cells expressing mPGES-1. Further, blockade of EGFR *in vivo* with erlotinib indicated the possibility of quenching the oncogenic drive exerted by malignant cooperation of the two signals (PGE₂ and EGF).

Materials and methods

Tumour samples

For PCa immunohistochemical study, formalin-fixed, paraffin-embedded tissue blocks from 52 radical prostatectomy specimens were retrieved from the archives of the University of Florence (Florence, Italy). Informed consent and approval according to the Helsinki Declaration were obtained from the local ethics review board. The specimens were reviewed by two genitourinary pathologists; pathological stage and tumour grade were assigned according to tumour/lympho-node/metastasis (TNM) (2010) classification and the Gleason score, respectively (Epstein *et al.* 2005, Edge *et al.* 2010). Twenty-five carcinomas were limited to the prostate (pT2, organ-confined PCa) and were moderately differentiated (Gleason score=6), whereas 27 cases (advanced PCa) were non-organ-confined tumours (pT3/pT4) with a high Gleason score (≥ 7) (Table 1). The median age of patients was 67.7 years (range 41–78 years).

Immunohistochemical analysis of tumour samples

Tissue slides were deparaffinised in xylene and dehydrated in ethanol. Microwave pre-treatment in EDTA (pH 9.0) (for EGFR) or in citrate buffer (pH 6.0) (for mPGES-1 and $\alpha 6$ -integrin) was performed for 20 min. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide (v/v) for 10 min and with 3% BSA (w/v) for 30 min. The slides were incubated with primary antibodies targeting

Table 1 Gene expression of vimentin, fibronectin and ahnak in DU145 cells expressing mPGES-1

Gene	Mean 2 ^{-(ΔC_t)}	s.d.
Vimentin	12.1	2
Fibronectin	2	0.1
Ahnak	1.6	0.2

α 6-integrin (1:100; Santa Cruz, Heidelberg, Germany), mPGES-1 (1:50; Thermo Scientific, Waltham, MA, USA) and EGFR (1:100; Cell Signalling, Leiden, The Netherlands) followed by chromogenic visualization using Immuno-peroxidase Secondary Detection System kits (Chemicon, Billerica, MA, USA). In particular, sections were incubated for 15 min in the appropriate species-specific biotinylated secondary antibodies and then with streptavidin-conjugated HRP for 15 min. After incubation they were exposed to 3,3-diaminobenzidine tetrahydrochloride (Sigma) for 10 min to produce a brown reaction product. After counterstaining with hematoxylin, slides were washed thoroughly, dehydrated, cleared in xylene and mounted. Staining intensity was scored as negative (no staining) or positive (brown colour).

Cell lines

DU145 WT (passages 5–20, ATCC HTB-81, certified by STRA) is a PCa cell line with high constitutive expression of mPGES-1 (Hanaka *et al.* 2009). DU145 mPGES-1 knockdown (mPGES-1^{KD} cells, passages 8–20) and non-target shRNA (mPGES-1^{SC} cells, 8–20) cells were obtained and cultured as described (Hanaka *et al.* 2009). PC-3 WT (passages 8–20, ATCC CRL-1435, certified by STRA) and LNCaP WT (passages 5–15, ATCC CRL-1740, certified by STRA) PCa cells were from ATCC. Cells were grown in RPMI (Euroclone, Pero Milano, Italy) and supplemented with 10% FBS (v/v). Human umbilical vein endothelial cells (HUVEC, passages 3–10) were from Lonza (Basel, Switzerland) (C2519A, certified by expression of CD31/105, vWFVIII, and positivity for acetylated low-density lipoprotein uptake). Cells were grown in endothelial growth medium (EGM-2) (Clonetics, Lonza) and supplemented with 10% FBS (v/v).

Transient mPGES-1 silencing

For siRNA transfection, the siRNAs sequence (human mPGES-1: 5'-CGGGCTAAGAATGCAGACTTT-3') was from Qiagen. The day before transfection, cells were trypsinized and 3×10^5 cells were seeded in six-well plates. Transient transfection of siRNA was carried out using Lipofectamin 2000 (Invitrogen) according to the manufacturer's instructions. Cells were assayed 72 h after transfection.

mPGES-1 shRNA transfection

Lenti vector plasmids for mPGES-1 knock down (Sigma) and mPGES-1+/+ (p Lenti vector with C-terminal

Myc-DDK tag-NM_004878) were obtained from Sigma and Origene (Origene, Rockville, MD, USA), respectively. psPAX2 packaging plasmid (12260) and pMDG.2 envelope plasmid (12259) were obtained from Addgene (Cambridge, MA, USA).

All the plasmids were sequence-verified. To generate mPGES-1 knock down (mPGES-1^{KD}) cells or mPGES-1 overexpressing (+/+) cells, 1×10^6 HEK293 cells (Life Technologies) were transfected with 2.25 μ g of PAX2 packaging plasmid, 0.75 μ g of PMD2G envelope plasmid and 3 μ g of pLKO.1 hairpin vector utilizing 12 μ l of Lipofectamine 2000 on 10 cm plates. Polyclonal populations of transduced cells were generated by infection with 1 multiplicity of infectious units (MOI) of lentiviral particles. Three days after infection, cells were selected with 10 μ g/ml puromycin (Gibco) or 20 μ g/ml neomycin/kanamycin (Sigma) for 1 week.

Epithelial-mesenchymal transition PCR array

The expression of 88 human Epithelial-mesenchymal transition (EMT) genes was profiled in DU145 cells using the EMT-RT² Profiler PCR Arrays (SAAB Bioscience, Qiagen). Total RNA was isolated using an RNA Mini kit (Qiagen) and reverse transcribed using an RT-PCR kit (Qiagen). Relative expression was determined for each of the 88 genes using the formula $2^{-\Delta C_t}$.

Real-time PCR

Total RNA was obtained using an RNA Mini kit (Qiagen). RNA (0.5 μ g) was reverse transcribed using a RT-PCR kit (Bio-Rad). Premixed primers for vimentin, fibronectin, ahnak, ITGB1, Nanog, Oct4 and GAPDH (as internal control) were from Applied Biosystems. Real-time PCR was performed using SYBR Green Supermix (Bio-Rad) according to the manufacturer's instructions. RT-PCR was performed using an iCycler iQ5 PCR Detection System. The results are expressed as $2^{-\Delta C_t}$ or fold increase.

Western blot

Tumour cells (5×10^5) were seeded in 6 cm plates in medium with 10% fetal bovine serum (FBS) (v/v) for 96 h, then lysed and analysed. Where indicated, cells were treated with PGE₂ (1 μ mol/l), erlotinib (10 μ mol/l), NS398 (10 μ mol/l) or [2-(6-chloro-1*H*-phenanthro-(9,10-*d*)imidazol-2-yl)isophthalonitrile, MF63 (10 μ mol/l). PGE₂ and NS398 were from Sigma, erlotinib was from Santa Cruz and MF63 was from AbMole (Houston, TX, USA). To assess

translocation of β -catenin from cytosol to nucleus, cells were trypsinized and homogenized on ice in lysis buffer containing 0.1 mmol/l EGTA, 0.1 mmol/l EDTA, 10 mmol/l Hepes, 10 mmol/l KCl, protease and phosphatase inhibitors. After incubation on ice for 15 min, Nonidet-P-40 was added to cell lysates, which were then centrifuged (3900 g, 30 s). The supernatant contained the cytosolic fraction, while the pellet was solubilized in lysis buffer containing 1 mmol/l EGTA, 1 mmol/l EDTA, 20 mmol/l Hepes, 10 mmol/l NaCl, 1% protease and phosphatase inhibitors (v/v), followed by incubation on ice for 10 min and centrifuging (5480 g, 5 min). The supernatant contained the nuclear fraction. An equal amount of proteins was loaded on SDS-PAGE gel and transferred to a nitrocellulose membrane. Western blot was performed as described by Donnini *et al.* (2012). Sources of antibodies were: anti-vimentin and anti-fibronectin, Sigma; anti- α -tubulin, Abcam (Cambridge, UK); anti- β -catenin, anti- α 6 integrin and anti- β 1 integrin, Santa Cruz; anti-P-Tyrosine, anti-EGFR, anti-caspase3 and anti-P-ERK1/2, Cell Signalling; anti-PGE₂ synthases, anti-COX synthases, anti-PGDH, anti-PGT and anti-EP receptors, Cayman Chemicals; anti-E-cadherin, DAKO (Milan, Italy). Images were digitalized with CHEMI DOC Quantity One software, blots were analysed in triplicate by densitometry using NIH Image 1.60B5 Software, and arbitrary densitometric units were normalized for β -actin (Sigma), tubulin (Santa Cruz) or H2A (Abcam, UK).

Tumour growth and lung metastasis in immunodeficient mice

Experiments were performed according to Italian and EEC guidelines for animal care and welfare (EEC Law No. 86/609). The experiments were approved by the Italian Ministry of Health (215/2011-B). To assess the contribution of mPGES-1 to the anti-tumour activity of erlotinib, immunodeficient mice (5-week-old male athymic mice, Harlan, Indianapolis, IN, USA) were inoculated s.c. in the right flank with 20×10^6 DU145 cells (mPGES-1^{SC} or mPGES-1^{KD}). When tumours reached a volume of 70–100 mm³, the animals were randomly assigned to treatment with erlotinib (50 mg/kg, three times a week by gavage). The first treatment is reported as day 1. Serial calliper measurements of perpendicular diameters were used to calculate tumour volume in mm³ with the formula: shortest diameter $\times$ longest diameter $\times$ thickness of tumour in millimeter. After treatment, animals were sacrificed and tumours were collected and split in two parts. One part was immediately frozen in liquid

nitrogen for western blot. The other part was embedded in Tissue-Tek O.C.T. (Sakura, Torrance, CA, USA) and frozen in liquid nitrogen for histology (Donnini *et al.* 2007). For histology, see [Supplementary Data](#), see section on [supplementary data](#) given at the end of this article.

To assess the contribution of mPGES-1 to lung metastases, DU145 and PC-3 PCa cells (mPGES-1^{SC} or mPGES-1^{KD}) were suspended in PBS at a density of 20×10^6 cells/ml, and 250 μ l of suspension was injected into the tail vein. To investigate whether EGFR inhibition affected the invasive activity of mPGES-1, cells were pre-treated with erlotinib (10 μ mol/l) for 72 h before injection. After 7 weeks, immunodeficient mice were sacrificed, lungs removed and fixed in Bouin's solution and the number of metastatic colonies counted.

MTT assay

Cell proliferation was quantified by Vybrant MTT cell proliferation assay as described (Donnini *et al.* 2007). Briefly, tumour cells (5×10^3) were seeded in 96-multiwell plates in medium with 10% serum for 24 h and then, where indicated, exposed to erlotinib (0.1–10 μ mol/l) for 96 h in 10% FBS (v/v). Results are reported as 540 nm absorbance/well.

Adhesion

DU145 cells were maintained in 10% FBS (v/v) and then trypsinized; 5×10^4 cells/ml in 1% FBS (v/v) medium were seeded in 96 multiwell plates coated with human fibronectin and incubated for 2 h at 37 °C. The wells were washed gently with PBS and adherent cells were fixed and stained with Diff-Quik. Adherent cells were counted by microscope in five random fields at 200 $\times$.

Tumour-endothelium adhesion

Tumour-endothelium adhesion was performed using the CytoSelect tumour-endothelium adhesion assay kit according to the manufacturer's instructions (Cell Biolabs, San Diego, CA, USA). Briefly, HUVEC cells (10×10^5 cells/well in 48 multiwell plates) were maintained in 10% FBS (v/v) for 48 h. After monolayer formation, DU145 cells were harvested and 1×10^6 cells/ml were suspended in serum-free medium and incubated for 1 h in the presence of CytoTracker. Cells were washed twice and added to the endothelial cell monolayer. After 1 h cells were lysed and the fluorescence read at 480 nm/520 nm. Where indicated, endothelial cells were pre-treated for 4 h with TNF α to increase cell–cell adhesion (Sheski *et al.* 1999).

Transendothelial migration

HUVEC cells (8×10^5 cells/well in the filter of a 48-well transwell plate) were maintained in 10% FBS (v/v) for 48 h. After monolayer formation, DU145 cells were harvested and 1×10^6 cells/ml were suspended in serum-free medium and incubated for 1 h in the presence of CytoTracker. Cells were washed twice with serum-free medium and 2×10^5 cells were added to the upper side of the transwell plate. After 2 h the medium in the lower side of the plate was collected and centrifuged. Migrant tumour cells were lysed and fluorescence measured at 480 nm/520 nm.

Cell viability assay

Tumour cells at a density of 5×10^5 cells/ml were incubated for 24 or 48 h in medium with 0.1% FBS (v/v). After incubation, the numbers of dead cells stained with trypan blue and total cells were evaluated by optical microscope. The number of dead cells was reported as a percentage of total cells.

Flow cytometry

Tumour cells were harvested and 3.5×10^4 cells were incubated in ice for 30 min with primary antibody, then washed in PBS and exposed to secondary antibody for an additional 30 min. Surface CD44 and CD24 (Abcam) were quantified by flow cytometry using unlabelled monoclonal or polyclonal Ab followed by fluorescein isothiocyanate (FITC) or tetramethylrhodamine (TRIC)-labelled secondary antibodies. Cells were analysed by flow cytometry using a FACScan flow cytometer (Becton-Dickinson, Franklin Lakes, NJ, USA). Data was acquired by CellQuest and plotted using FlowJo (Tree Star, Ashland, OR, USA).

Clonogenic assay

Tumour cells were plated in 60 mm culture dishes (1000 cells per dish) in medium containing 10% FBS. After 24 h cells were treated with erlotinib or MF63 (1–10 $\mu\text{mol/l}$) in 10% FBS (v/v) and kept in a humidified incubator for 10 days. Colonies (> 50 cells) were fixed and stained with 0.05% crystal violet (w/v) (Sigma) in 10% ethanol (v/v), counted and photographed.

Statistical analysis

Results were expressed as means $\pm$ S.E.M., analysed by Student's *t*-test and/or one-way ANOVA with Bonferroni's

correction. A value of $P < 0.05$ was considered to denote statistical significance.

Results

mPGES-1 promotes the mesenchymal and stem cell-like phenotype in PCa cells

We investigated the correlation of mPGES-1 expression (immunohistochemistry) with staging and grading in a series of PCa cases. Overall, mPGES-1 expression was detected in 12/25 (48%) organ-confined PCa and in 21/27 (77.7%) advanced PCa (Fig. 1A). In human advanced PCa samples, both mPGES-1 and EGFR were co-expressed in a high percentage of cases ($n = 19/27$, 70.3%; Fig. 1A). In the same group, $\alpha 6$ -integrin, a stem cell marker (Marthick & Dickinson 2012, Hoogland *et al.* 2014), was negative or weakly stained ($n = 19/27$; Fig. 1B). By contrast, only 7/25 (28%) of organ-confined tumours showed co-expression of mPGES-1 and EGFR (Fig. 1A, 70.3% vs 28%, see also panel a and b from an organ confined PCa sample vs c and d from an advanced PCa sample).

In DU145 cell line isolated from a castration-resistant human brain metastasis of PCa, characterized by mPGES-1 expression (mPGES-1^{SC}) (Hanaka *et al.* 2009), the knock down for mPGES-1 (stable or transient mPGES-1^{KD}) did not affect PGE₂ receptor expression (EP1-4), while it obliterated PGE₂ output ($> 90\%$, $P < 0.001$ vs mPGES-1^{SC}) (A and B, and Supplementary Figure 1, see section on supplementary data given at the end of this article). The large PGE₂ loss occurred despite a slight increase in cyclooxygenase-2 (COX-2) expression, while other enzymes involved in PGE₂ metabolism were either unchanged (e.g. COX-1), or only negligibly changed (e.g. the cytosolic isoform, cPGES, the microsomal type 2 isoform, mPGES-2, the prostaglandin transporter, PGT and the enzyme implicated in PGE₂ degradation, 15-hydroxyprostaglandin dehydrogenase (PGDH)) (Fig. 2A). Compared to DU145 WT, transfection of cells with the empty vector (mPGES-1^{SC}) did not affect the PGE₂ signalling cascade (Fig. 2A). Similar results were obtained in experiments of transiently silenced mPGES-1 cells (Supplementary Figure 2A).

Because PGE₂ regulates genes involved in EMT in tumour cell lines (Dohadwala *et al.* 2006), we assessed whether constitutively high mPGES-1 expression in DU145 affected their mesenchymal-cell-like phenotype with respect to mPGES-1^{KD} cells. The results showed that $\sim 1/4$ of EMT-related genes ($n = 22/88$) were influenced by high expression of intrinsic mPGES-1 (Fig. 2B). Notable

A

PCa	No of patients (%)			
	mPGES-1+/EGFR+	mPGES-1-/EGFR+	mPGES-1+/EGFR-	mPGES-1-/EGFR-
Organ-confined	7 (28%)	4 (16%)	5 (20%)	9 (36%)
Advanced	19 (70.3%)	3 (11.1%)	2 (7.4%)	3 (11.1%)

B

Figure 1

Immunohistochemical expression of mPGES-1, EGFR and α 6-integrin in prostate cancer. (A) Representative images of mPGES-1 and EGFR expression in organ-confined (a and b) or advanced (c and d) prostate

cancer. (B) Representative images of mPGES-1 and α 6-integrin expression in advanced prostate cancer.

changes occurred in transcription factors known to induce EMT, such as Snail, Slug (SNAIL2 gene) and ZEB, and in several genes coding for cytoskeletal proteins, such as E-cadherin, vimentin, fibronectin and ahnak. Western blot and immunofluorescence analysis illustrated the marked loss of vimentin, fibronectin and ahnak and the increased expression of E-cadherin in stably and transiently silenced mPGES-1^{KD} cells (C and D). Reduced expression of vimentin, fibronectin and ahnak was also detected by quantitative RT-PCR (Table 1). Treatment of mPGES-1^{KD} cells with PGE₂ (1 μ mol/l, 24 h) reversed both vimentin and fibronectin expression, confirming the involvement of PGE₂ in this process (Fig. 2E). In line with the role of PGE₂ in cancer cell growth and E-cadherin expression (Castellone *et al.* 2005, Lu *et al.* 2012), we found massive translocation of β -catenin into the nucleus of

DU145 mPGES-1^{SC} cells, while it remained localized in the cytoplasm of mPGES-1^{KD} cells (Fig. 2E and F).

We also observed a prevalence of stem-cell-like markers, regarded as indicators of tumour invasiveness, in DU145 mPGES-1^{SC} compared to mPGES-1^{KD} cells. This was indicated by the large increase in the CD44⁺/CD24⁻ ratio, the decrease in α 6-integrin and the increase in β 1 integrin, as well as transcription factors Nanog and Oct4 in mPGES-1^{SC} (Fig. 3A, B and C), all pluripotency maintaining factors overexpressed in PCa stem cells (Klarmann *et al.* 2009, Rentala *et al.* 2010, Marthick & Dickinson 2012, Nanta *et al.* 2013, Hoogland *et al.* 2014). Similar results were obtained for the PC-3 cell line. PC-3 cells expressed constitutive mPGES-1, and knocking down the enzyme significantly reduced PGE₂ output (>60%, $P < 0.01$ vs mPGES-1^{SC}), promoted epithelial

Figure 2

mPGES-1 promotes EMT in DU145 cells. (A) Expression of enzymes involved in arachidonic acid cascade in DU145 WT, mPGES-1^{SC} and mPGES-1^{KD} cell lines in basal condition (10% FCS) measured by western blot. (B) EIA analysis of PGE₂ production measured in medium conditioned by DU145 cells. Results (three experiments run in duplicate) are expressed as pg/ml of PGE₂. ****P* < 0.001 vs mPGES-1^{SC}. (C and D) Representative images and

quantification of western blot analysis of E-cadherin, vimentin, fibronectin and ahnak expression in DU145 cells. **P* < 0.05, ***P* < 0.01 and ****P* < 0.001 vs DU145 mPGES-1^{SC}. (E) Western blot analysis of fibronectin and vimentin in mPGES-1^{KD} cells treated with PGE₂ (1 μmol/l, 24 h). (F) Western blot analysis of β-catenin localization in DU145 mPGES-1^{SC} and mPGES-1^{KD} cells. Nuc, nucleus; Cyt, cytoplasm.

phenotype, decreased cell clonogenicity and reduced the expression of stem cell markers (Supplementary Figure 3A, B, C, D, E and F, see section on supplementary data given at the end of this article). We also recorded anchorage-independent cell viability in mPGES-1^{SC} cells, in contrast to the drastic decline seen in mPGES-1^{KD} cells, associated with caspase-3 activation (Fig. 3D and E, and Supplementary Figure 3G and H). Adhesion studies with fibronectin coated-wells or endothelial cells revealed that mPGES-1^{SC} cells rapidly adhered (2 h) to the matrix or endothelium (whether or not it had been activated by TNFα to favour cell–cell interaction and transmigration), whereas mPGES-1^{KD} cells displayed a significantly delayed adhesion (F and G). Since knock down of mPGES-1 in cells does not affect cell survival *in vitro*, as measured by MTT assay (Abs 0.95 ± 0.08 and 0.88 ± 0.11 for DU145 mPGES-1^{SC} and mPGES-1^{KD}

cells; Abs 0.74 ± 0.06 and 0.79 ± 0.09 for PC-3 mPGES-1^{SC} and mPGES-1^{KD} cells respectively), or cell apoptosis in suspension up to 24–48 h, we conclude that the inhibition of adhesion in mPGES-1^{KD} cells depends on the modification of cytoskeletal organization, for example of vimentin and fibronectin. Finally, by measuring trans-endothelial migration, we showed a far greater ability (nearly threefold) of mPGES-1^{SC} than mPGES-1^{KD} cells to cross cell layers (Fig. 3H), indicating the involvement of mPGES-1/PGE₂ signalling in prostate tumour invasiveness.

Inhibition of mPGES-1 activity suppresses stem-like phenotype

Further evidence that the mPGES-1-PGE₂ cascade enhances PCa cell aggressiveness was obtained by

Figure 3

EGFR activation mediates mPGES-1/PGE₂-dependent EMT of DU145 cells. (A) FACS analysis for CD24 and CD44 expression in DU145 mPGES-1^{SC} and mPGES-1^{KD} cells, and (B) western blot analysis and quantification of α6 and β1-integrin expression in mPGES-1^{SC} and mPGES-1^{KD} cells. Data are representative of three different experiments and quantification was performed by Image J. **P* < 0.01 vs DU145 mPGES-1^{SC} (C) RT-PCR analysis of Nanog and Oct4 expression in mPGES-1^{SC} and mPGES-1^{KD} DU145 cells. Data are reported as fold increase vs mPGES-1^{SC} cells. ***P* < 0.01 vs DU145 mPGES-1^{SC}. (D) Cell viability of DU145 mPGES-1^{SC} and mPGES-1^{KD} in suspension in 0.1% of serum. Results are expressed as % of dead cells. ***P* < 0.01 and ****P* < 0.001 vs DU145 mPGES-1^{SC}. (E) Western blot analysis of caspase 3 activation in DU145 cells grown in suspension for the indicated time. (F) Adhesion of DU145 mPGES-1^{SC} and mPGES-1^{KD} untreated or pretreated with PGE₂ (1 μmol/l, 96 h) on fibronectin-coated 96-well plate.

Cell adhesion was evaluated after 2 h of incubation in 1% serum. Results (three experiments in triplicate) are expressed as % of adherent cells relative to untreated mPGES-1^{SC}. ***P* < 0.01 vs mPGES-1^{SC}; ****P* < 0.01 vs mPGES-1^{KD}. (G) CytoTracker labeled DU145 mPGES-1^{SC} or mPGES-1^{KD} cells were allowed to attach to untreated or TNFα-pre-treated HUVEC monolayers in 48-well plates for 1 h. Adherent cells were lysed and quantified. Results (three experiments in duplicate) are expressed as fold increase to the adhesion of mPGES-1^{SC} on untreated HUVEC. ***P* < 0.01 vs mPGES-1^{SC}. (H) Migration of DU145 mPGES-1^{SC} and mPGES-1^{KD} toward HUVEC monolayer. CytoTracker labeled tumor cells were seeded in the upper side of 48-well-transwell and migration was evaluated after 2 h by measuring the fluorescence in the lower side of the well. Data are reported as relative fluorescence unit of three experiments run in duplicate. ***P* < 0.01 vs DU145 mPGES-1^{SC}.

inhibiting mPGES-1 activity with the selective inhibitor MF63 (Xu *et al.* 2008). MF63 (10 μmol/l, 24–48 h) significantly inhibited PGE₂ production and reversed the mesenchymal phenotype in DU145 and PC-3 cells, promoting E-cadherin and inhibiting vimentin expression (Fig. 4A, B and C). MF63 also upregulated α6-integrin and significantly reduced cell clonogenicity (Fig. 4D and E).

To complement the above findings, we also transfected mPGES-1 in LNCaP PCA cells, isolated from a castration-resistant human lymph node metastases lacking constitutive mPGES-1 (Supplementary Figure 4A, see section on supplementary data given at the end of this article). As expected, forced expression of mPGES-1 in LNCaP cells promoted an increase in PGE₂ production, cell growth and development of the mesenchymal phenotype as documented by E-cadherin decrease (Supplementary Figure 4B, C, D and E).

mPGES-1 induces growth and lung metastasis formation

In light of the observed link between mPGES-1/PGE₂ signalling, EMT and stemness markers in PCA cells, we

investigated whether the presence of mPGES-1 in DU145 and PC-3 cells influenced their growth and metastatic invasion *in vivo*.

In tumours induced by inoculating nude mice with mPGES-1^{SC} or mPGES-1^{KD} cells, the volume measurements (here reported at days 12 and 21) showed significant differences, growth being 2.3-fold higher in DU145 mPGES-1^{SC} than mPGES-1^{KD} tumours, and 4.9-fold higher in PC-3 mPGES-1^{SC} than mPGES-1^{KD} tumours (Fig. 5A). Consistently, Ki-67 showed denser immunostaining in mPGES-1^{SC} than mPGES-1^{KD} tumours (Fig. 5B). Accordingly, the Ki67 score was 45 ± 2.9% and 57 ± 3.8% for DU145 and PC-3 mPGES-1^{SC} respectively and 21 ± 1.9% and 29 ± 1.8% for DU145 and PC-3 mPGES-1^{KD} respectively, indicating a higher proliferation rate in cells overexpressing mPGES-1.

Western blot (Fig. 5C) and immunohistochemistry of tumours (Fig. 5D) revealed abundant mPGES-1 and vimentin expression in mPGES-1^{SC}, contrasting with the absence of these two proteins in mPGES-1^{KD} tumours.

We also investigated the contribution of mPGES-1 expression to PCA metastasis by injecting DU145 and PC-3 cells (mPGES-1^{SC} and mPGES-1^{KD} cells for both cell lines)

Figure 4

Pharmacological inhibition of mPGES-1 controls EMT markers, $\alpha 6$ -integrin and EGFR expression, and reduces prostate cancer cells growth. (A). EIA analysis of PGE₂ production measured in medium conditioned by DU145 or PC-3 cells after 48 h of treatment with MF63 (10 μ mol/l). Results (three experiments run in duplicate) are expressed as pg/ml of PGE₂. ** $P < 0.01$ vs basal. (B, C and D) Western blot analysis of E-cadherin, vimentin and

$\alpha 6$ -integrin expression after MF63 treatment (10 μ mol/l). (E). Quantification of DU145 and PC-3 colonies in the presence or absence of MF-63 10 μ mol/l. Data are reported as the number of colonies of three experiments in triplicate. * $P < 0.05$ and ** $P < 0.01$ vs basal PC-3; # $P < 0.05$ and ### $P < 0.001$ vs basal DU145.

in the tail vein of nude mice. In mice injected with DU145 or PC-3 mPGES-1^{SC}, the number of lung colonies was 18 ± 2 and 20 ± 3.8 , respectively. In contrast, knock down of mPGES-1 significantly reduced the numbers of colonies (10 ± 1.9 and 3.3 ± 2.8 respectively, Fig. 5E).

These results demonstrate that mPGES-1/PGE₂ signalling plays a significant role in prostate tumour growth and metastasis development.

mPGES-1 induces EGFR expression in prostate tumours and mediates EGFR-dependent tumour growth

It is well documented that PGE₂ favours EGF/EGFR-induced oncogenicity by directly phosphorylating EGFR (Buchanan et al. 2003, Donnini et al. 2007). However, it is unknown whether mPGES-1/PGE₂ signalling modulates EGFR expression levels. We measured EGFR expression in DU145 mPGES-1^{SC} and mPGES-1^{KD} cells, in tumours from mice inoculated with the respective cell lines and in DU145 and PC-3 treated with MF63. We found distinctly higher EGFR expression levels in the mPGES-1^{SC} group than in the mPGES-1^{KD} group (A, B and C and Supplementary Figure 2B). Consistently, p-ERK1/2, a known downstream effector of EGFR signalling, was higher in mPGES-1^{SC} than mPGES-1^{KD} tumours (Fig. 6D), suggesting that EGFR signalling plays a role in mPGES-1 enhancement of tumour growth.

Moreover, treatment of DU145 and PC-3 mPGES-1^{SC} cells with mPGES-1 inhibitor MF63 (10 μ mol/l) and DU145 mPGES-1^{SC} cells with COX-2 inhibitor NS398 (10 μ mol/l, 96 h) inhibited EGFR expression (Fig. 6E and F), while exogenous PGE₂ (1 μ mol/l, 96 h) increased EGFR

protein levels in DU145 mPGES-1^{KD} cells, supporting involvement of PGE₂ in promoting EGFR over-expression in prostate tumours.

Further evidence of involvement of mPGES-1/PGE₂ signalling in EGFR expression was obtained in experiments *in vitro* and *in vivo* using erlotinib, a known inhibitor of EGFR. *In vitro*, erlotinib administration to DU145 cells (10 μ mol/l) abrogated EGFR phosphorylation and downregulated vimentin expression (Fig. 6G). Phosphorylation of EGFR was independent of EGF expression, which was affected in mPGES-1^{KD} cells but not in mPGES-1^{SC} (Supplementary Figure 5, see section on supplementary data given at the end of this article). Erlotinib also reduced cell viability in DU145 mPGES-1^{KD} cells and functionally halved the number of cell colonies (number of colonies: mPGES-1^{SC} = 58 ± 4 vs mPGES-1^{KD} = 27 ± 5) (Fig. 6H, I, J, K and L). *In vivo*, erlotinib decreased tumour growth in DU145 mPGES-1^{SC} and mPGES-1^{KD}-bearing mice with respect to the vehicle-treated group (area under curve: mPGES-1^{SC} + erlotinib = 12360 vs mPGES-1^{KD} + erlotinib = 5664, Fig. 6M). Erlotinib treatment was more effective in reducing tumour volume when mPGES-1 was knocked down (Fig. 6I), but it did not affect the number of metastases for DU145 and PC-3 cell lines (number of metastases: mPGES-1^{SC} = 20 ± 4.8 and mPGES-1^{KD} = 7.5 ± 3.5 for DU145; mPGES-1^{SC} = 17.7 ± 4.2 and mPGES-1^{KD} = 5.3 ± 3.4 for PC-3).

All together, this data provides clear evidence of the role played by the mPGES-1/PGE₂ pathway in inducing a mesenchymal phenotype and stemness in PCa cells, thus reinforcing EGFR tumorigenic drive.

Figure 5

mPGES-1 expression controls *in vivo* tumor growth, vimentin and EGFR expression. (A). Tumor volume measured in athymic mice inoculated with DU145 and PC-3 mPGES-1^{SC} or mPGES-1^{KD} cells after 12 or 21 days. * $P < 0.05$ and ** $P < 0.01$ vs mPGES-1^{SC}. (B). Immunohistochemical analysis of Ki67 expression in tumor specimens derived from mPGES-1^{SC} or mPGES-1^{KD}. Data are representative of five tumor specimens for both tumor cell types.

(C and D) Western blot and immunohistochemical analysis of vimentin expression in xenograft tumor tissues. Data are representative of five tumor specimens for both tumor cell types. (E). Quantification and images of lung metastasis after injection in mice tail vein of DU145 or PC-3 mPGES-1^{SC} or mPGES-1^{KD} cells. Images: grey frame: DU145; black frame: PC-3. * $P < 0.05$ and ## $P < 0.01$ vs mPGES-1^{SC}.

Discussion

The present study shows that by eliciting mesenchymal and stem-cell-like traits and EGFR expression, the tumour intrinsic inflammatory mPGES-1/PGE₂ pathway cooperates with the EGFR oncogene to promote an aggressive PCa phenotype.

As an experimental paradigm we used DU145 and PC-3 cells in which mPGES-1 was stably or transiently knocked down by mRNA silencing (mPGES-1^{KD}), comparing them with prostate cells containing a negative control non-targeting shRNA plasmid (mPGES-1^{SC}). Further, evidence of the specificity of mPGES-1/PGE₂ signalling in PCa aggressiveness was obtained by pharmacological inhibition of the enzyme with the selective MF63 inhibitor (Xu *et al.* 2008).

Inflammation plays a role in the development and progression of many cancers, including PCa, and multiple pro-inflammatory molecules are associated with PCa recurrence (Ørsted & Bojesen 2013). Here we investigated the contribution of the mPGES-1/PGE₂ pathway to EMT, a process that promotes acquisition of mesenchymal traits, such as enhanced growth and migratory capacity, invasiveness and resistance to apoptosis, by epithelial cells. We observed that mPGES-1 knockdown influenced a set of genes promoting EMT in tumour cells, such as genes coding for transcriptional activity (Snail, Slug and ZEB), which were significantly downregulated. The effect on the cytoskeletal protein vimentin, which became undetectable in mPGES-1^{KD} and in cells treated with MF63, was particularly striking. A number of other changes occurred

Figure 6

mPGES-1 expression in cells mediates prostate tumor responsiveness to erlotinib. (A) Western blot analysis of the EGFR expression in DU145 mPGES-1^{SC} and mPGES-1^{KD} cells in basal condition or treated for 96 h with 1 μmol/l PGE₂. Graph: quantification of EGFR expression. Data (three experiments) represent the ratio between EGFR and actin. ***P* < 0.01 vs mPGES1^{SC} and ##*P* < 0.01 vs mPGES-1^{KD}. (B) Immunofluorescence analysis of EGFR expression in mPGES-1^{SC} and mPGES-1^{KD} cells. (C and D) EGFR expression and ERK 1/2 phosphorylation in tumor specimens derived from DU145 mPGES-1^{SC} and mPGES-1^{KD}. (E and F) Western blot analysis of EGFR expression in DU145 and PC-3 mPGES-1^{SC} treated with MF63 (10 μmol/l, 24–72 h), in DU145 mPGES-1^{SC} treated with NS398 (10 μmol/l, 96 h) and in DU145 mPGES-1^{KD} treated with PGE₂ (1 μmol/l, 96 h). Representative gels of three experiments. (G) Western blot analysis of EGFR phosphorylation

and vimentin expression in DU145 mPGES-1^{SC} cells treated with erlotinib (10 μmol/l, 96 h). Data are representative of three experiments. (H) MTT assay of DU145 mPGES-1^{SC} and mPGES-1^{KD} cells treated with erlotinib (0.01–10 μmol/l, 96 h). Data (three experiments in triplicate) are reported as cell death (%). (I) Representative colonies of DU145 mPGES-1^{SC} and mPGES-1^{KD} cells. (J) Quantification of DU145 mPGES-1^{SC} and mPGES-1^{KD} colonies in the presence or absence of erlotinib 1 and 10 μmol/l. Data are reported as Δ of mPGES-1^{SC} and mPGES-1^{KD} cell colonies in the presence of erlotinib over the control (%) and are the means of three experiments in duplicate. **P* < 0.05 vs mPGES-1^{SC}; ***P* < 0.01 vs mPGES-1^{KD}. (K) Tumor volume measured in athymic mice inoculated with DU145 mPGES-1^{SC} or mPGES-1^{KD} cells and treated with erlotinib (400 μg/mouse per three times per week, ip). #*P* < 0.05, ***P* < 0.01 and ****P* < 0.001 vs DU145 mPGES-1^{SC}.

in mPGES-1^{KD} cells. They included downregulation of insulin growth factor binding protein-4 (IGFBP-4) and the integrin β1 (ITGB1) gene, re-localization of β-catenin and overexpression of E-cadherin. All these markers are known to be associated with PCa aggressiveness (Damon *et al.* 1998, Miyake *et al.* 2000, Mohan & Baylink 2002, Bijnsdorp *et al.* 2013, Carbonell *et al.* 2013). Regulation of these markers may therefore be causally

related to the loss of function parameters observed in mPGES-1^{KD} cells.

mPGES-1 expression in PCa cells was clearly associated with stem-like features as demonstrated by the greater survival ability of mPGES-1^{SC} cells in suspension compared to mPGES-1^{KD} cells. Additional evidence of mPGES-1-linked stemness was a significant shift in the CD44/CD24 ratio, decreased β1-integrin, increased

$\alpha 6$ -integrin expression and increased transcription factors Nanog and Oct4 (Nanta *et al.* 2013). Collectively, these results provide evidence of involvement of mPGES-1/PGE₂ in promoting EMT and stemness in mPGES-1^{SC} tumour cells, since its ablation and inhibition impairs their inherent potential to survive in suspension and to transmigrate to endothelial cells.

EGFR studies provided another means to examine the interplay between PGE₂ input and oncogenic drive mediated by the EGFR system. The picture emerging is one of reciprocal activation producing vigorous PCa progression when both components (PGE₂ and EGF) of this circuit are maximally expressed, as in mPGES-1^{SC} cells, and conversely, a reduced outcome in mPGES-1^{KD} and in mPGES-1-inhibited cells, in which both components are downregulated. This circuit appears to be operant in the clinical setting here reported, as in human prostate tumours mPGES-1 and EGFR are concomitantly expressed in specimens with a high Gleason score compared to specimens of organ-confined lesions with a low Gleason score. Thus, mPGES-1/PGE₂ signalling empowers tumour cells to disseminate and seed metastases by activating EMT and stemness in PCa.

The present findings illustrate the role of mPGES-1 signalling in influencing EGFR-mediated oncogenicity and in contributing, in association with the EGFR pathway, to aggressiveness in PCa. Indeed, erlotinib treatment reduced tumour development in the mPGES-1^{SC} group to approximately the same level as that observed in mPGES-1^{KD} tumours. Further, ablation of PGE₂ production significantly reduced lung metastasis in mice, indicating that mPGES-1 signalling plays a key role in EMT and stemness of PCa cells (Oskarsson *et al.* 2014). The combination of mPGES-1 knockdown or pharmacological inhibition of mPGES-1 by MF63 with erlotinib results in a more effective strategy to inhibit PCa cell growth. Ability to undergo EMT and acquire stem-cell-like features enables tumours to expand, spread and resist chemotherapy/target therapy (Clevers 2011, Hoggatt *et al.* 2013). PGE₂ release in the tumour microenvironment was recently shown to be responsible for tumour initiation and repopulation, hence inhibitors of PGE₂ production interfere with tumour progression and chemoresistance (Kurtova *et al.* 2015). Our study demonstrates that mPGES-1 ablation or inhibition in human PCa cells suppresses their overall oncogenic drive and reduces their stemness and invasiveness. We conclude that the mPGES-1 gene may be considered a signature gene for identifying a subtype of rapidly progressing prostate tumours, which, in the case of overexpression of EGFR,

may benefit from combined treatment with inhibitors of EGFR, tyrosine kinase and PGE₂.

Supplementary data

This is linked to the online version of the paper at <http://dx.doi.org/10.1530/ERC-15-0277>.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

The project was funded by Associazione Italiana Ricerca sul Cancro (AIRC) IG: 10731 and Istituto Toscano Tumori Grant Proposal 2010. F Finetti was a SIF (Società Italiana di Farmacologia)-Takeda 2013 fellow, and E Terzuoli was a FIRC (Fondazione Italiana per la Ricerca sul Cancro) fellow.

References

- Arteaga CL 2002 Epidermal growth factor receptor dependence in human tumors: more than just expression? *Oncologist* **7** (Suppl 4) 31–39. (doi:10.1634/theoncologist.7-suppl_4-31)
- Augello MA, Den RB & Knudsen KE 2014 AR function in promoting metastatic prostate cancer. *Cancer Metastasis Reviews* **15** 399–411. (doi:10.1007/s10555-013-9471-3)
- Bijnsdorp IV, Geldof AA, Lavaei M, Piersma SR, van Moorselaar RJ & Jimenez CR 2013 Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients. *Journal of Extracellular Vesicles* **2** article 22097. (doi:10.3402/jev.v2i0.22097)
- Buchanan FG, Wang D, Bargiacchi F & DuBois RN 2003 Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. *Journal of Biological Chemistry* **278** 35451–35457. (doi:10.1074/jbc.M302474200)
- Canil CM, Moore MJ, Winkvist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M *et al.* 2005 Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. *Journal of Clinical Oncology* **23** 455–460. (doi:10.1200/JCO.2005.02.129)
- Carbonell WS, DeLay M, Jahangiri A, Park CC & Aghi MK 2013 $\beta 1$ integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. *Cancer Research* **73** 3145–3154. (doi:10.1158/0008-5472.CAN-13-0011)
- Castellone MD, Teramoto H, Williams BO, Druey KM & Gutkind JS 2005 Prostaglandin E2 promotes colon cancer cell growth through a Gs- α - β -catenin signaling axis. *Science* **310** 1504–1510. (doi:10.1126/science.1116221)
- Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cötting D, Droegge C, Interhalder R *et al.* 2012 Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). *Clinical Cancer Research* **18** 6049–6057. (doi:10.1158/1078-0432.CCR-12-2219)
- Clevers H 2011 The cancer stem cell: premises, promises and challenges. *Nature Medicine* **17** 313–319. (doi:10.1038/nm.2304)

- Coussens LM, Zitvogel L & Palucka AK 2013 Neutralizing tumor-promoting chronic inflammation: a magic bullet? *Science* **339** 286–291. (doi:10.1126/science.1232227)
- Damon SE, Maddison L, Ware JL & Plymate SR 1998 Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. *Endocrinology* **139** 3456–3464.
- Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC *et al.* 2006 Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. *Cancer Research* **66** 5338–5345. (doi:10.1158/0008-5472.CAN-05-3635)
- Donnini S, Finetti F, Solito R, Terzuoli E, Sacchetti A, Morbidelli L, Patrignani P & Ziche M 2007 EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. *FASEB Journal* **21** 2418–2430. (doi:10.1096/fj.06-7581com)
- Donnini S, Finetti F, Terzuoli E, Giachetti A, Iñiguez MA, Hanaka H, Fresno M, Rådmark O & Ziche M 2012 EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity. *Oncogene* **31** 3457–3466. (doi:10.1038/onc.2011.503)
- Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A 2010 *AJCC Cancer Staging Manual*, 7th edn, pp 457–468. New York, NY: Springer-Verlag.
- Epstein JI, Allsbrook WC Jr, Amin MB & Egevad LL 2005 ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *American Journal of Surgical Pathology* **29** 1228–1242. (doi:10.1097/01.pas.0000173646.99337.b1)
- Gravis G, Bladou F, Salem N, Gonçalves A, Esterni B, Walz J, Bagattini S, Marcy M, Brunelle S & Viens P 2008 Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. *Annals of Oncology* **19** 1624–1628. (doi:10.1093/annonc/mdn174)
- Hammarsten P, Rudolfsson SH, Henriksson R, Wikström P & Bergh A 2007 Inhibition of the epidermal growth factor receptor enhances castration-induced prostate involution and reduces testosterone-stimulated prostate growth in adult rats. *Prostate* **67** 573–581. (doi:10.1002/pros.20529)
- Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. *Cell* **144** 646–674. (doi:10.1016/j.cell.2011.02.013)
- Hanaka H, Pawelzik SC, Johnsen JI, Rakonjac M, Terawaki K, Rasmuson A, Sveinbjörnsson B, Schumacher MC, Hamberg M, Samuelsson B *et al.* 2009 Microsomal prostaglandin E synthase 1 determines tumor growth *in vivo* of prostate and lung cancer cells. *PNAS* **106** 18757–18762. (doi:10.1073/pnas.0910218106)
- Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, Ferraro F *et al.* 2013 Differential stem- and progenitor-cell trafficking by prostaglandin E2. *Nature* **495** 365–369. (doi:10.1038/nature11929)
- Hoogland AM, Verhoef EI, Roobol MJ, Schröder FH, Wildhagen MF, van der Kwast TH, Jenster G & van Leenders GJ 2014 Validation of stem cell markers in clinical prostate cancer: α 6-integrin is predictive for non-aggressive disease. *Prostate* **74** 488–496. (doi:10.1002/pros.22768)
- Jakobsson PJ, Thorén S, Morgenstern R & Samuelsson B 1999 Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. *PNAS* **96** 7220–7225. (doi:10.1073/pnas.96.13.7220)
- Kamei D, Murakami M, Sasaki Y, Nakatani Y, Majima M, Ishikawa Y, Ishii T, Uematsu S, Akira S, Hara S *et al.* 2009 Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. *Biochemical Journal* **425** 361–371. (doi:10.1042/BJ20090045)
- Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB & Farrar WL 2009 Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. *Clinical & Experimental Metastasis* **26** 433–446. (doi:10.1007/s10585-009-9242-2)
- Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, Chen F, Roh TT, Lay E, Ho PL *et al.* 2015 Blocking PGE₂-induced tumour repopulation abrogates bladder cancer chemoresistance. *Nature* **517** 209–213. (doi:10.1038/nature14034)
- Lu D, Han C & Wu T 2012 Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGFR/ β -catenin signaling axis. *Oncogene* **31** 842–857. (doi:10.1038/onc.2011.287)
- Mantovani A, Allavena P, Sica A & Balkwill F 2008 Cancer-related inflammation. *Nature* **454** 436–444. (doi:10.1038/nature07205)
- Marthick JR & Dickinson JL 2012 Emerging putative biomarkers: the role of α 2 and α 6 integrins in susceptibility, treatment, and prognosis. *Prostate Cancer* **2012** 298732. (doi:10.1155/2012/298732)
- Miyake H, Pollak M & Gleave ME 2000 Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. *Cancer Research* **60** 3058–3064.
- Mohan S & Baylink DJ 2002 IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. *Journal of Endocrinology* **175** 19–31. (doi:10.1677/joe.0.1750019)
- Nabhan C, Lestingi TM, Galvez A, Tolzien K, Kelby SK, Tsarwhas D, Newman S & Bitran JD 2009 Erlotinib has moderate single-agent activity in chemotherapy naïve castration-resistant prostate cancer: final results of a phase II trial. *Urology* **74** 665–671. (doi:10.1016/j.urology.2009.05.016)
- Nanta R, Kumar D, Meeker D, Rodova M, Van Veldhuizen PJ, Shankar S & Srivastava RK 2013 NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2R γ null mice by regulating Bmi-1 and microRNA-128. *Oncogenesis* **2** e42. (doi:10.1038/oncsis.2013.5)
- Ørsted DD & Bojesen SE 2013 The link between benign prostatic hyperplasia and prostate cancer. *Nature Reviews. Urology* **10** 49–54. (doi:10.1038/nrurol.2012.192)
- Oskarsson T, Batlle E & Massagué J 2014 Metastatic stem cells: sources, niches, and vital pathways. *Cell Stem Cell* **14** 306–321. (doi:10.1016/j.stem.2014.02.002)
- van Rees BP, Sivula A, Thorén S, Yokozaki H, Jakobsson PJ, Offerhaus GJ & Ristimäki A 2003 Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. *International Journal of Cancer* **107** 551–556. (doi:10.1002/ijc.11422)
- Rental S, Yalavarthy PD & Mangamoori LN 2010 α 1 and β 1 integrins enhance the homing and differentiation of cultured prostate cancer stem cells. *Asian Journal of Andrology* **12** 548–555. (doi:10.1038/aja.2010.20)
- Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Chun FH, Haese A, Kollermann J, Graefen M *et al.* 2007 Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. *Clinical Cancer Research* **13** 6579–6584. (doi:10.1158/1078-0432.CCR-07-1257)
- Schrecengost R & Knudsen KE 2013 Molecular pathogenesis and progression of prostate cancer. *Seminars in Oncology* **40** 244–258. (doi:10.1053/j.seminoncol.2013.04.001)
- Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK & Batra SK 2012 Targeting the EGFR signaling pathway in cancer therapy. *Expert Opinion on Therapeutic Targets* **16** 15–31. (doi:10.1517/14728222.2011.648617)

- Sha W, Olesch C, Hanaka H, Rådmark O, Weigert A & Brüne B 2013 Necrosis in DU145 prostate cancer spheroids induces COX-2/mPGES-1-derived PGE₂ to promote tumor growth and to inhibit T cell activation. *International Journal of Cancer* **133** 1578–1588. (doi:10.1002/ijc.28181)
- Sheski FD, Natarajan V & Pottratz ST 1999 Tumor necrosis factor- α stimulates attachment of small cell lung carcinoma to endothelial cells. *Journal of Laboratory and Clinical Medicine* **133** 265–273. (doi:10.1016/S0022-2143(99)90083-5)
- Takahashi R, Amano H, Satoh T, Tabata K, Ikeda M, Kitasato H, Akira S, Iwamura M & Majima M 2014 Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells. *Biomedicine & Pharmacotherapy* **68** 71–77. (doi:10.1016/j.biopha.2013.10.008)
- Takeda H, Miyoshi H, Tamai Y, Oshima M & Taketo MM 2004 Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas. *British Journal of Cancer* **90** 701–704. (doi:10.1038/sj.bjc.6601584)
- Wieduwilt MJ & Moasser MM 2008 The epidermal growth factor receptor family: biology driving targeted therapeutics. *Cellular and Molecular Life Sciences* **65** 1566–15684. (doi:10.1007/s00018-008-7440-8)
- Xu D, Rowland SE, Clark P, Giroux A, Côté B, Guiral S, Salem M, Ducharme Y, Friesen RW, Méthot N et al. 2008 MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. *Journal of Pharmacology and Experimental Therapeutics* **326** 754–763. (doi:10.1124/jpet.108.138776)
- Xu LW, Qian M, Jia RP, Xu Z, Wu JP, Li WC, Huang WB & Chen XG 2012 Expression and significance of microsomal prostaglandin synthase-1 (mPGES-1) and Beclin-1 in the development of prostate cancer. *Asian Pacific Journal of Cancer Prevention* **13** 1639–1644. (doi:10.7314/APJCP.2012.13.4.1639)

Received in final form 4 June 2015

Accepted 23 June 2015

Made available online as an Accepted Preprint

25 June 2015